📰 Context Therapeutics News
Context Therapeutics News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Context Therapeutics. Real-time updates on events, politics, business and more.
June 19, 2024
At the same time. The evidence so far has not been conclusive about whether convalesce convalescent plasma works, twhowhen to administer it and what dose to use. Kelly, what do we expect to hear . Reporter here it is a sunday evening on the eve of the president s own Political Convention and theres an announcement about a potential treatment option for doctors and their patients who have coronavirus. The timing is interesting. Is it being done safely . Those are some of the questions well put to...
May 2, 2024
CTIM-76Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers
May 2, 2024
Financing includes new and existing leading healthcare investors
March 31, 2024
Context Therapeutics Inc. (NASDAQ:CNTX – Get Free Report) saw a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 17,000 shares, an increase of 57.4% from the February 29th total of 10,800 shares. Approximately 0.1% of the company’s shares are short sold. Based on an […]
March 29, 2024
Context Therapeutics Inc. (NASDAQ:CNTX – Get Free Report) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 17,000 shares, an increase of 57.4% from the February 29th total of 10,800 shares. Currently, 0.1% of the company’s shares are short sold. Based on an […]
November 13, 2023
Context Therapeutics (NASDAQ:CNTX) has announced its third-quarter results, highlighting its progress in advancing its lead candidate, CTIM-76, a Claudin 6...
October 30, 2023
Context Therapeutics Inc. (NASDAQ:CNTX – Get Free Report) was the target of a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 44,900 shares, a growth of 14.5% from the September 30th total of 39,200 shares. Based on an average daily trading volume, of 36,800 […]
October 24, 2023
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: ...
September 14, 2023
Maxim Group started coverage on shares of Context Therapeutics (NASDAQ:CNTX – Free Report) in a research report sent to investors on Monday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $4.00 price objective on the stock. Context Therapeutics Trading Down 2.9 % Shares of CNTX stock opened at $1.02 on Monday. […]
September 14, 2023
Maxim Group started coverage on shares of Context Therapeutics (NASDAQ:CNTX – Free Report) in a report issued on Monday morning, MarketBeat reports. The brokerage issued a buy rating and a $4.00 price target on the stock. Context Therapeutics Stock Performance Context Therapeutics stock opened at $1.02 on Monday. The firm has a market cap of […]